Jagsonpal Pharmaceuticals is currently trading at Rs. 194.40, up by 17.05 points or 9.61% from its previous closing of Rs. 177.35 on the BSE.
The scrip opened at Rs. 177.35 and has touched a high and low of Rs. 194.40 and Rs. 175.20 respectively. So far 19903 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 5 has touched a 52 week high of Rs. 203.25 on 03-Aug-2021 and a 52 week low of Rs. 75.00 on 15-Apr-2021.
Last one week high and low of the scrip stood at Rs. 194.40 and Rs. 156.75 respectively. The current market cap of the company is Rs. 470.78 crore.
The promoters holding in the company stood at 70.34%, while Institutions and Non-Institutions held 0.12% and 29.54% respectively.
Jagsonpal Pharmaceuticals has entered into an agreement with Suvinys Developers for supply of product Dydrogesterone.
Suvinys Developers will supply Dydrogesterone to Jagsonpal Pharmaceuticals as per the terms and conditions as mentioned in the agreement.
Jagsonpal Pharmaceutical is among India’s premiere pharmaceutical companies.
The company has substantial research and development, manufacturing, marketing and distribution facilities.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
